论文部分内容阅读
目的:探讨脂质体紫杉醇联合卡铂治疗复发性转移性乳腺癌的疗效。方法:选取2010年6月至2012年6月我院收治的复发性转移性乳腺癌患者80例进行回顾性分析,随机分成观察组和对照组两组,每组40例,观察组采用脂质体紫杉醇联合卡铂治疗,对照组仅采用卡铂治疗,观察两组治疗效果和不良反应发生情况。结果:观察组治疗有效率和疾病控制率明显高于对照组,存在统计学意义(p<0.05);观察组生存期明显长于对照组,生存率明显高于对照组,存在统计学意义(p<0.05);观察组不良反应发生率明显低于对照组,存在统计学意义(p<0.05)。结论:脂质体紫杉醇联合卡铂治疗复发性转移性乳腺癌安全有效,是一种科学有效的治疗方法,值得临床推广。
Objective: To investigate the efficacy of liposomal paclitaxel combined with carboplatin in the treatment of recurrent metastatic breast cancer. Methods: Totally 80 patients with recurrent metastatic breast cancer admitted to our hospital from June 2010 to June 2012 were retrospectively analyzed and randomly divided into observation group and control group, with 40 cases in each group. The observation group was given lipid Paclitaxel combined carboplatin treatment, the control group only treated with carboplatin, the two groups observed the treatment effect and adverse reactions. Results: The treatment efficiency and disease control rate in the observation group were significantly higher than those in the control group (p <0.05). The survival time in the observation group was significantly longer than that in the control group, and the survival rate was significantly higher than that in the control group (p <0.05). The incidence of adverse reactions in the observation group was significantly lower than that in the control group (p <0.05). Conclusion: Liposome paclitaxel combined with carboplatin is safe and effective in the treatment of recurrent metastatic breast cancer. It is a scientifically effective treatment and worthy of clinical promotion.